The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease

Molecular and Cellular Neuroscience

Volumn 34, Issue 4, 2007, Pages 621-628

  Riddell, David R ^a   Zhou, Hua ^a   Comery, Thomas A ^a   Kouranova, Evguenia ^a   Lo, C Frederick ^a   Warwick, Helen K ^a   Ring, Robert H ^a   Kirksey, Yolanda ^a   Aschmies, Suzan ^a   Xu, Jane ^a   Kubek, Katie ^a   Hirst, Warren D ^a   Gonzales, Catherine ^a   Chen, Yi ^a   Murphy, Erin ^a   Leonard, Sarah ^a   Vasylyev, Dmytro ^a   Oganesian, Aram ^a   Martone, Robert L ^a   Pangalos, Menelas N ^a   Reinhart, Peter H ^a   Jacobsen, J Steve ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA AMYLOID PEPTIDE 40; BETA AMYLOID PEPTIDE 42; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR; TO 901317; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EFFUSION; FEAR; GENETIC TRANSCRIPTION; HIPPOCAMPUS; LIPID TRANSPORT; MALE; MEMORY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; ATP-BINDING CASSETTE TRANSPORTERS; DNA-BINDING PROTEINS; HIPPOCAMPUS; HUMANS; MALE; MEMORY; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

MUS; MUS MUSCULUS;

EID: 33947610707     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2007.01.011     Document Type: Article

References (36)

1. Bjorkhem I., and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 806-815
2. Burns M.P., Vardanian L., Pajoohesh-Ganji A., Wang L., Cooper M., Harris D.C., Duff K., and Rebeck G.W. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 98 (2006) 792-800
3. Comery T.A., Martone R.L., Aschmies S., Atchison K.P., Diamantidis G., Gong X., Zhou H., Kreft A.F., Pangalos M.N., Sonnenberg-Reines J., Jacobsen J.S., and Marquis K.L. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 8898-8902
4. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., and Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11735-11740
5. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., and Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41 (2004) 193-202
6. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
7. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., and Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9 (2002) 305-318
8. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5856-5861
9. Fryer J.D., Demattos R.B., McCormick L.M., O'Dell M.A., Spinner M.L., Bales K.R., Paul S.M., Sullivan P.M., Parsadanian M., Bu G., and Holtzman D.M. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280 (2005) 25754-25759
10. Fukumoto H., Deng A., Irizarry M.C., Fitzgerald M.L., and Rebeck G.W. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 277 (2002) 48508-48513
11. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
12. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., Blain J.F., Naus K.E., McIsaac S.A., Parkinson P.F., Chan J.Y., Tansley G.H., Hayden M.R., Poirier J., Van Nostrand W., and Wellington C.L. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280 (2005) 43243-43256
13. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., and Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5161-5166
14. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., and Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10 (2004) 719-726
15. Koldamova R.P., Lefterov I.M., Ikonomovic M.D., Skoko J., Lefterov P.I., Isanski B.A., DeKosky S.T., and Lazo J.S. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 278 (2003) 13244-13256
16. Koldamova R., Staufenbiel M., and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280 (2005) 43224-43235
17. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., and Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280 (2005) 4079-4088
18. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
19. Manelli A.M., Stine W.B., Van Eldik L.J., and LaDu M.J. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci. 23 (2004) 235-246
20. Maren S., and Holt W. The hippocampus and contextual memory retrieval in Pavlovian conditioning. Behav. Brain Res. 110 (2000) 97-108
21. Quinet E.M., Savio D.A., Halpern A.R., Chen L., Miller C.P., and Nambi P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 45 (2004) 1929-1942
22. Riddell D.R., Christie G., Hussain I., and Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 11 (2001) 1288-1293
23. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., and Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000) 2831-2838
24. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 4 (2005) 841-852
25. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6460-6464
26. Stratman N.C., Castle C.K., Taylor B.M., Epps D.E., Melchior G.W., and Carter D.B. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem. Phys. Lipids 137 (2005) 52-61
27. Sun Y., Yao J., Kim T.W., and Tall A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 278 (2003) 27688-27694
28. Trommer B.L., Shah C., Yun S.H., Gamkrelidze G., Pasternak E.S., Stine W.B., Manelli A., Sullivan P., Pasternak J.F., and LaDu M.J. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol. Dis. 18 (2005) 75-82
29. Ulven S.M., Dalen K.T., Gustafsson J.A., and Nebb H.I. Tissue-specific autoregulation of the LXRalpha gene facilitates induction of apoE in mouse adipose tissue. J. Lipid Res. 45 (2004) 2052-2062
30. Wahrle S.E., Jiang H., Parsadanian M., Hartman R.E., Bales K.R., Paul S.M., and Holtzman D.M. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280 (2005) 43236-43242
31. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
32. Wang L., Schuster G.U., Hultenby K., Zhang Q., Andersson S., and Gustafsson J.A. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13878-13883
33. Wellington C.L. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin. Genet. 66 (2004) 1-16
34. Whitney K.D., Watson M.A., Collins J.L., Benson W.G., Stone T.M., Numerick M.J., Tippin T.K., Wilson J.G., Winegar D.A., and Kliewer S.A. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol. 16 (2002) 1378-1385
35. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 (2004) 7-10
36. Zelcer N., and Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116 (2006) 607-614